Palomar (NASDAQ:PLMR) CFO Sells $161,825.04 in Stock

by · The Cerbat Gem

Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) CFO T Christopher Uchida sold 1,326 shares of the company’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $122.04, for a total value of $161,825.04. Following the completion of the sale, the chief financial officer directly owned 12,370 shares in the company, valued at approximately $1,509,634.80. The trade was a 9.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

T Christopher Uchida also recently made the following trade(s):

  • On Saturday, January 31st, T Christopher Uchida sold 545 shares of Palomar stock. The stock was sold at an average price of $121.74, for a total transaction of $66,348.30.
  • On Thursday, January 29th, T Christopher Uchida sold 1,326 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total transaction of $161,825.04.
  • On Wednesday, January 28th, T Christopher Uchida sold 2,103 shares of Palomar stock. The shares were sold at an average price of $119.88, for a total transaction of $252,107.64.
  • On Tuesday, November 18th, T Christopher Uchida sold 782 shares of Palomar stock. The shares were sold at an average price of $128.84, for a total value of $100,752.88.

Palomar Stock Up 0.5%

NASDAQ:PLMR traded up $0.63 on Monday, hitting $124.22. The stock had a trading volume of 240,836 shares, compared to its average volume of 180,129. The stock has a market cap of $3.29 billion, a price-to-earnings ratio of 19.38 and a beta of 0.44. The business’s 50-day simple moving average is $127.67 and its two-hundred day simple moving average is $123.57. Palomar Holdings, Inc. has a 52-week low of $104.47 and a 52-week high of $175.85.

Palomar (NASDAQ:PLMR – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.56 by $0.45. Palomar had a return on equity of 21.93% and a net margin of 22.59%.The business had revenue of $244.66 million during the quarter, compared to analysts’ expectations of $207.98 million. During the same quarter in the prior year, the business posted $1.23 earnings per share. As a group, equities research analysts anticipate that Palomar Holdings, Inc. will post 5.99 EPS for the current year.

Hedge Funds Weigh In On Palomar

Institutional investors have recently bought and sold shares of the business. Salomon & Ludwin LLC purchased a new position in shares of Palomar in the 3rd quarter valued at $25,000. Richardson Financial Services Inc. grew its position in shares of Palomar by 210.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock worth $25,000 after buying an additional 147 shares during the last quarter. Allworth Financial LP lifted its position in Palomar by 1,970.0% during the second quarter. Allworth Financial LP now owns 207 shares of the company’s stock valued at $32,000 after acquiring an additional 197 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Palomar during the fourth quarter worth $32,000. Finally, Clearstead Advisors LLC boosted its position in shares of Palomar by 31.0% in the 3rd quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock worth $46,000 after purchasing an additional 94 shares in the last quarter. 90.25% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Palomar

Here are the key news stories impacting Palomar this week:

  • Positive Sentiment: Palomar closed the acquisition of The Gray Casualty & Surety Company, expanding its surety capabilities and product mix — a strategic tuck‑in that can add premium, diversify risk exposure and support growth in specialty lines. BCP Completes Sale of The Gray Casualty & Surety Company
  • Neutral Sentiment: Palomar will report Q4 and full‑year 2025 results after the close on Feb 11, 2026, with a conference call Feb 12 — an event that typically drives short‑term volume and volatility as investors update estimates and listen for management commentary on reserve development, underwriting margin, and growth. Earnings Release & Conference Call
  • Negative Sentiment: Multiple insiders (including the CEO, President, CFO and other senior executives) sold shares on Jan. 29 and Jan. 31, reducing positions by low-single-digit percentages in many cases. Heavy insider selling can signal liquidity taking or tax/comp planning, but it may concern some investors about insider confidence or timing ahead of earnings. Representative coverage of recent insider sales is here. CEO Sells Stock (Example)

Analysts Set New Price Targets

Several research analysts recently commented on PLMR shares. Keefe, Bruyette & Woods lifted their price target on Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. increased their price target on Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Weiss Ratings raised shares of Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, January 14th. Finally, Wall Street Zen raised shares of Palomar from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $159.50.

Check Out Our Latest Research Report on PLMR

Palomar Company Profile

(Get Free Report)

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

Further Reading